ClinicalTrials.gg
RecruitingNCT06408246ACE-DUpdated Mar 5, 2026

ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression

A Phase 2 interventional study of Guanfacine and Sertraline in Depression, sponsored by Stanford University. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Stanford University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 79 studies testing sertraline in Depression — 6 open to participants now, 7 under way, none of them phase 3. Sertraline · Depression.

Planned enrollment
22nd of 78
162 · median 91
Started
2026
the only one that year
Phase 2
8 of 79
1 open now
Registered
76th of 79
by date

Among the 79 studies testing sertraline in Depression, this one is the 22nd largest by planned enrollment of the 78 interventional ones that give a count, is the only one that started in 2026, is one of 8 in phase 2, and was the 76th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

6 of the 79 studies testing sertraline in Depression are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About sertraline

Sertraline: first FDA approval 1991 (ZOLOFT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies testing sertraline in Depression, or all of them as a file.
02

Study summary

The purpose of this study is to understand how a psychotropic medication called guanfacine affects brain network functioning in humans, and how this function interacts with cognitive impairments in people experiencing depressive symptoms.

Read the detailed description

The investigators will conduct a parallel-group, double-blind randomized trial at Stanford Bay Area and Chicago sites, identifying 162 participants across Stanford University and the University of Illinois Chicago with a prominent clinical cognitive signature (C+) and relative absence of the signature (C-).

If you are eligible and choose to participate based off of your answers on the screening survey, the investigators will call you on the number you have provided to verify participants' responses and answer any additional questions you may have about the study.

The first screening visit will consist of obtaining participants' informed consent to participate in the study, completing cognitive testing, answering questions about participants' thoughts and feelings, and providing information about participants' medical and psychiatric history.

If participants are deemed eligible at this phase, the investigators will ask participants to come in for an in-person medical screening (up to 2 hours). This in-person medical screen visit will consist of getting your vitals taken (heart rate/blood pressure), undergoing a blood draw, and providing a urine sample. Additionally, people who are or suspect they may become pregnant throughout the course of the study will be given a pregnancy test.

If a participant is deemed eligible after the medical screen, the investigators will ask participants to come in for another in-person visit (2 hours) that would involve a non-invasive brain scan. Participants will then be randomized to receive guanfacine plus sertraline or placebo plus sertraline for an 8 week treatment phase.

Starting week 1 and for every week during the 8-week treatment phase, participants will complete nightly medication log surveys, passive sampling with the BiAffect application, and conduct cognitive testing. Additionally, starting week 1 and every week thereafter, participants will attend a virtual physician visit. At the end of week 8, the investigators will conduct an MRI visit that resembles the initial MRI visit. Participants will be unblinded over weeks 9-10 to arrange for the participants' transition out of the trial.

03

Conditions studied

  • Depression

Keywords

  • Precision Psychiatry
  • Depression
  • Cognitive Symptoms
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and lifestyle considerations (see Section 5.3) and availability for the duration of the study
  3. Male or female
  4. Age 18-60 years
  5. Fluent and literate in English
  6. Meets diagnostic criteria for MDE (major depressive episode), and criteria for current or recurrent nonpsychotic MDD using the Mini International Neuropsychiatric Interview (MINI Plus)79
  7. A total score of 10 or higher on the PHQ-8 at initial screening, including:

    a. Endorsement of anhedonia, as indexed by a response of "more than half the days" or "nearly every day" to Item 1 ("Little interest or pleasure in doing things") or endorsement of persistent negative mood, as indexed by a response of "more than half the days" or "nearly every day" to Item 2 ("Feeling down, depressed, or hopeless")

  8. Meets criteria for cognitive dysfunction (C+ subgroup) or absence of cognitive dysfunction (C- subgroup) based on results from computerized behavioral testing of cognitive control performance (WebNeuro) and from fMRI scanning using the Go/No-Go task.

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Presence of one or more of the following conditions established via the participant's medical record and confirmed using the MINI Plus:

    • bipolar disorder (I, II, not otherwise specified, current or lifetime)
    • psychosis (current or lifetime)
    • moderate to severe alcohol or substance use disorders (current)
    • post-traumatic stress disorder (PTSD; current)
    • obsessive compulsive disorder (OCD; current or lifetime)
    • attention deficit hyperactivity disorder (ADHD; current or lifetime)
    • eating disorders (ED; current)
  2. Suicidality with active plan
  3. Severe impediment to vision, hearing, and/or hand movement
  4. Current or lifetime history of medical illness or brain injury that may interfere with assessments
  5. Pregnant, breastfeeding, or unwilling or unable to use adequate throughout the study (females of only)
  6. 3.0T MRI scanner (e.g., metal in the body, claustrophobia)
  7. Concurrent participation in other intervention studies
  8. Current use of psychotropic medications contraindicated by guanfacine or sertraline
  9. General medical condition or disorder that is deemed by study physicians to be unsafe for GIR as reported by patient or found on medical screening. This may include:

    • Cardiac-related exclusions:

      • Resting heart rate (HR) \< 55 beats per minute (bradycardia)
      • Systolic blood pressure (SBP) \< 90 mmHg or diastolic blood pressure (DBP) \< 60 mmHg (hypotension)
      • Current symptoms suggestive of cardiac dysfunction based on clinician assessment (e.g., persistent chest pain, palpitations, dizziness, fainting)
    • Renal-related exclusions:

      • \< 60 mL/min/1.73 m²
      • Current symptoms suggestive of kidney dysfunction based on clinician assessment
    • Hepatic-related exclusions:

      • > 2×
      • AST > 2× ULN
      • Current symptoms suggestive of liver dysfunction based on clinician assessment
    • Thyroid-related exclusions:

      • TSH outside normal laboratory reference range
      • Current symptoms suggestive of thyroid dysfunction based on clinician assessment
  10. Use of substance deemed by the study physician to be unsafe for use with guanfacine
  11. Current use of a strong inhibitor (e.g., ketoconazole) or inducer (e.g., carbamazepine) that, in the judgment of the study clinician, may alter guanfacine plasma concentrations and cannot be safely discontinued for the duration of the study.
  12. Unwillingness to verify biotype classification via fMRI
  13. Unwillingness or inability to use a computer or access a computer for assessments.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    Sertraline + Guanfacine

    We will conduct a parallel-group, double-blind randomized trial at Stanford Bay Area and Chicago sites, identifying 160 participants with a prominent clinical cognitive signature (C+) and relative absence of the signature (C-). We will enrich for C+, the signature of interest, at a 2:1 ratio. Participants will be randomly assigned to receive guanfacine (shown to ameliorate cognitive control deficits in our preliminary data) plus sertraline or placebo plus sertraline.

    Drug: Guanfacine

  • Experimental
    Sertraline + Placebo

    We will conduct a parallel-group, double-blind randomized trial at Stanford Bay Area and Chicago sites, identifying 160 participants with a prominent clinical cognitive signature (C+) and relative absence of the signature (C-). We will enrich for C+, the signature of interest, at a 2:1 ratio. Participants will be randomly assigned to receive guanfacine (shown to ameliorate cognitive control deficits in our preliminary data) plus sertraline or placebo plus sertraline.

    Drug: Sertraline

Interventions

  • Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.

  • Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.

06

What researchers measure

Primary outcomes

  1. Remission of depressive symptoms

    A score of \<=5 on the PHQ-9

    Time frame: 8 weeks

Secondary outcomes

  1. Change in disability

    Score on the Sheehan Disability Scale which ranges from 0 to 30

    Time frame: 8 weeks

  2. Change in quality of Life

    Score on the Short Form 8 Health Survey (SF-8) which ranges from 0 to 100

    Time frame: 8 weeks

07

Study locations

2 of 2 sites recruiting
  • Stanford Psychiatry and Behavioral Sciences Department
    Palo Alto, California 94305, United States
    Recruiting
  • University of Illinois at Chicago
    Chicago, Illinois 60607, United States
    Recruiting
    • Jun Ma, PhD · Contact
    • Jun Ma, PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Oct 2028, 30 months after the start.

Of 144 non-industry phase 2 interventional studies under Depression, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 30 months is below that.

Counting every sponsor, half of 198 studies reached it within 31 months; a quarter within 18 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2024
First posted
May 10, 2024
StartActual
Mar 3, 2026
Primary completionEst.
Oct 1, 2028
CompletionEst.
Feb 1, 2029
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06408246
Responsible party
Leanne Williams (Professor, Stanford University) — Principal investigator
First posted
May 10, 2024
Start date
Mar 3, 2026
Primary completion
Oct 1, 2028 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Mar 5, 2026

Study contacts

Leyla Boyar, BA
Contact
ljboyar@stanford.edu
6504989326
Isabelle Wydler Clinical Research Coordinator, BA
Contact
iwydler@stanford.edu
6507364393
Leanne Williams, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Guanfacine · Sertraline

Start the discussion